Endo International plc 2015 Annual Report
Endo international plc 2015 annual report
endo international plc
2015 annual report

By the Numbers

Endo has approximately


Employees worldwide
Endo total 2015 revenue was


Endo markets its products directly to physicians through a global sales force of over

1,200 individuals

Endo completed


acquisitions: Par Pharmaceutical, Auxilium Pharmaceuticals and Aspen Holdings
Endo holds 352 U.S. issued patents, 190 U.S. patent applications pending, 856 foreign issued patents and 150 foreign patent applications pending
Endo received FDA approval of BELBUCATM, the first and only buprenorphine buccal film for chronic pain; more than

100 million

U.S. adults suffer from chronic pain

five additional

development programs focused on new potential indications for XIAFLEX®
U.S. Generic Pharmaceuticals has a portfolio of

1,200+ products

U.S. Generic Pharmaceuticals has approximately

130 ANDAs

currently under review with the FDA

Shaping the future

At Endo, we are committed to improving lives while creating value. Toward this goal, we seek to manage our Company for the future in order to create continued, sustainable growth. Our 2015 Digital Annual Report uses the metaphor of origami, the art of transforming a simple piece of paper into magnificent shapes, to illustrate this cycle of growth and the evolution of our core businesses: U.S. Branded, U.S. Generic and International Pharmaceuticals. We believe that our Key Values—leadership, teamwork, innovation, being results-driven and having a sharp customer focus—are what drives us to success in not only managing for the future, but also actively shaping it on behalf of our customers and shareholders.